Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.475 -3.63% 12.625 12.50 12.75 13.125 12.625 12.88 590,617 09:50:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 31

Futura Medical Share Discussion Threads

Showing 16876 to 16896 of 18700 messages
Chat Pages: Latest  676  675  674  673  672  671  670  669  668  667  666  665  Older
DateSubjectAuthorDiscuss
19/6/2019
09:33
Proactive Investor Interview: Sorry - I am struggling to upload the link here.
alchemist1010
19/6/2019
08:24
Pleased to see recruitment completed on time and on budget, well done FUM.
rrr
19/6/2019
08:18
Should hopefully see a nice steady rise to maybe 35/40 over the coming months and assuming data is good at the end of the year the sky is the limit then
ragnarr
19/6/2019
06:49
Ties in nicely with this "Futura Medical PLC’s (LON:FUM) data from a Phase 3 trial of its MED2005 erectile dysfunction treatment could drive the share price up over 500% according to analysts at Liberum Capital, who on Monday initiated the stock with a ‘buy’ rating and 60p target price. In its initiation note, the ‘house’ broker for the AIM-listed pharma firm said they expected positive data from the Phase 3 trial for MED2002, which is expected to be delivered by December this year." So maybe November we will know the outcome.
j777j
19/6/2019
06:14
James Barder, Chief Executive Officer, Futura Medical said: "We are extremely pleased to complete recruitment of over 1,000 patients for the first European Phase 3 study, "FM57", of MED2005, within our expected timelines and budget and I would like to thank all parties involved in reaching this important milestone. The Company's focus is now on the Phase 3 data read-out at the end of the year, which we hope will significantly clinically de-risk MED2005, and help provide commercial partners with greater certainty around the potential opportunity it presents." The potential market for this product is large with potential peak sales in excess of US $1 billion. If MED2005 is approved, there is an estimated $560M prescription-only market potential (sources: Decision Resources and Cello), and an estimated incremental $660M+ market potential as an over-the-counter (OTC) product, in markets where switch is possible. (source: Ipsos Mori forecasts commissioned by Futura).
j777j
18/6/2019
16:01
Good old Grannypants always knows best.
j777j
17/6/2019
13:33
As my dear old gran used to tell me "all good things come to those that wait"
ragnarr
17/6/2019
12:27
Simply need US bio fund or two onboard and the shares will rerate.
j777j
17/6/2019
11:19
Liberum's figures are ultra conservative and that simply amplifies the value here.
j777j
17/6/2019
10:56
Thanks J777J.
rrr
17/6/2019
10:47
Liberum "The multi-billion dollar market for erectile dysfunction (ED) therapies continues to be dominated by PDE-5 inhibitors, despite a slow onset of action and negative side-effects. We believe Futura’s MED2005 addresses these issues and expect positive P3 data in December. Our confidence is driven by compelling P2 data, a non-binary set of potential outcomes, and a rock-solid safety profile. With a market cap of just £50m vs a peak sales potential of c.£500m, we think the market misses this low risk potential. BUY." "Key catalyst due by Dec 2019 Unlike with most drug discovery businesses, there is not long to wait for the key catalyst, with the headline P3 data due by December. This could drive >500% upside." Yes >500% upside!! "Liberum view: Headline data from FM57 is due by the end of December 2019, which is the key catalyst for the shares. This data alone should be enough to secure a significant outlicensing agreement, but more importantly de-risk the confirmatory second P3 study." "We have not provided much detail on potential competition in the pipeline, as frankly we do not see any at this stage."
j777j
17/6/2019
10:34
Just a game of patience here, happy holding.. chart looks good though! One on the move, outdoors be under valued too (C4XD) dyor as usual
ny boy
17/6/2019
08:49
>>>martinelwick You can download the note from Research tree https://www.research-tree.com/companies/uk/pharmaceuticals/futura-medical
timbo003
17/6/2019
07:46
Hi can you provide the link.
martinelwick
17/6/2019
07:18
Liberum 60p price target fair value and 137p high end
j777j
17/6/2019
07:10
Bullish research report from Liberum today."High probability of success,low valuation......"
j777j
12/6/2019
14:18
I always blame my partner !
mikethebike4
12/6/2019
07:51
Down to Liberum finding realInstitutional support.
wantage
12/6/2019
01:57
The repartition is vapid.
glavey
11/6/2019
10:16
Between 8 aug 2016 and 5 sep 2016,the share price went from 21p to 80p on positive news regarding the med gel. Can have quite some moves.
j777j
11/6/2019
09:57
Needs some decent new US investors onboard. The rating Fum gets here is minuscule to how it would be valued stateside,for a co with so much potential. Smaller caps in general are cheapest they have been for decades.
j777j
Chat Pages: Latest  676  675  674  673  672  671  670  669  668  667  666  665  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200122 10:52:32